Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 27,31 € (+66,73 %). La mediana es de 29,99 € (+83,09 %).
| Comprar |
25 |
| Mantener |
11 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit
A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadia’s operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » Más en de.investing.com
Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference
At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » Más en de.investing.com
Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results
Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » Más en de.investing.com
FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin
The FDA has granted fast-track status to Acadia’s compound remlifanserin for the treatment of hallucinations and delusions in Alzheimer’s psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in September–October 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » Más en de.investing.com
Acadia Pharmaceuticals insider sells nearly half of direct holdings
James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, sold 11,421 shares in an open-market transaction on June 26, 2026—about 46.6% of his direct holdings—at a weighted average price of $26.08, leaving him with 13,088 shares. The sale, executed under a pre-established Rule 10b5-1 plan, was his largest single open-market disposition and coincided with a share rally after an EMA recommendation for Daybue. Company fundamentals remain strong, with Q1 2026 revenue of $268.1 million and ongoing late-stage pipeline programs. The filings show no derivative or indirect holdings were involved, and recent larger sales reflect reduced available capacity rather than disclosed discretionary changes in strategy. » Más en finance.yahoo.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 302,19 M | 27,28 % |
| Beneficio bruto | 271,21 M | 23,85 % |
| Beneficio neto | 47,25 M | 22,74 % |
| EBITDA | 71,02 M | 75,28 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 2944,84 M € |
Número de acciones | 172,83 M |
Máximo/mínimo de 52 semanas | 28,13 € - 14,41 € |
| Dividendos | No |
Beta | 0,89 |
Ratio P/E | 8,80 |
Ratio PEG | 0,24 |
Ratio P/B | 2,33 |
Ratio P/S | 2,70 |
Perfil de la empresa
ACADIA Pharmaceuticals Inc., una empresa biofarmacéutica, se centra en el desarrollo y la comercialización de fármacos de molécula pequeña que abordan necesidades médicas no cubiertas en los trastornos del sistema nervioso central. La compañía ofrece NUPLAZID (pimavanserina) para el tratamiento de las alucinaciones y delirios asociados a la psicosis de la enfermedad de Parkinson. Su cartera de desarrollo incluye pimavanserina, en desarrollo de fase 3 para el tratamiento de la psicosis de la enfermedad de Alzheimer y de los síntomas negativos de la esquizofrenia; trofinetida, un análogo sintético novedoso, en desarrollo de fase 3 para el tratamiento del síndrome de Rett; ACP-044, un analgésico no opioide novedoso de primera clase de administración oral, en desarrollo de fase 2 para el tratamiento del dolor agudo y crónico; y ACP-319, un modulador alostérico positivo del receptor muscarínico, en desarrollo de fase 1 para el tratamiento de la esquizofrenia y de la cognición en la enfermedad de Alzheimer. ACADIA Pharmaceuticals Inc. fue fundada en 1993 y tiene su sede en San Diego, California.
| Nombre | Acadia Pharmaceuticals |
| CEO | Catherine E. Owen Adams |
| Sede | San Diego,
ca Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 27/05/2004 |
| Empleados | 797 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | ACAD |
Frankfurt | DR6.F |
Düsseldorf | DR6.DU |
London | 0A4W.L |
SIX | DR6.SW |
München | DR6.MU |